Literature DB >> 23035022

Guidelines on similar biologics: regulatory requirements for marketing authorization in India.

Anurag Rathore1.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 23035022     DOI： 10.5731/pdajpst.2012.00886

Source DB:  PubMed          Journal:  PDA J Pharm Sci Technol        ISSN： 1079-7440


× No keyword cloud information.
  18 in total

1.  Therapeutic monoclonal antibodies and the need for targeted pharmacovigilance in India.

Authors:  M Kalaivani; Abhishank Singh; V Kalaiselvan
Journal:  MAbs       Date:  2015       Impact factor: 5.857

Review 2.  Regulatory and clinical considerations for biosimilar oncology drugs.

Authors:  Charles L Bennett; Brian Chen; Terhi Hermanson; Michael D Wyatt; Richard M Schulz; Peter Georgantopoulos; Samuel Kessler; Dennis W Raisch; Zaina P Qureshi; Z Kevin Lu; Bryan L Love; Virginia Noxon; Laura Bobolts; Melissa Armitage; John Bian; Paul Ray; Richard J Ablin; William J Hrushesky; Iain C Macdougall; Oliver Sartor; James O Armitage
Journal:  Lancet Oncol       Date:  2014-11-24       Impact factor: 41.316

Review 3.  Update on Biosimilars in Asia.

Authors:  Wen-Chan Tsai
Journal:  Curr Rheumatol Rep       Date:  2017-08       Impact factor: 4.592

4.  A comparison of asparaginase activity in generic formulations of E.coli derived L- asparaginase: In-vitro study and retrospective analysis of asparaginase monitoring in pediatric patients with leukemia.

Authors:  Hari Sankaran; Soumika Sengupta; Vaitashi Purohit; Anand Kotagere; Nirmalya Roy Moulik; Maya Prasad; Chetan Dhamne; Gaurav Narula; Shripad Banavali; Vikram Gota
Journal:  Br J Clin Pharmacol       Date:  2020-02-18       Impact factor: 4.335

5.  Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study.

Authors:  Neh Nupur; Nidhi Chhabra; Rozaleen Dash; Anurag S Rathore
Journal:  MAbs       Date:  2017-12-07       Impact factor: 5.857

6.  A prospective, open-label, randomised, parallel design study of 4 generic formulations of intramuscular L-asparaginase in childhood precursor B-cell acute lymphoblastic leukaemia (ALL).

Authors:  Suja Johnson; Chetan Dhamne; Hari Sankaran; Khushboo A Gandhi; Pallavi Rane; Nirmaly Roy Moulik; Shraddha Mahesh Jadhav; Murari Gurjar; Gaurav Narula; Shripad Banavali; Vikram Gota
Journal:  Cancer Chemother Pharmacol       Date:  2022-10-17       Impact factor: 3.288

Review 7.  Phase I (first-in-man) prophylactic vaccine's clinical trials: Selecting a clinical trial site.

Authors:  Shantanu Mehta; Vishal Goyal; Kavita Singh
Journal:  Perspect Clin Res       Date:  2015 Apr-Jun

8.  Potential impact of subsequent entry biologics in nephrology practice in Canada.

Authors:  Daniel J Martinusen; Clifford Lo; Judith G Marin; Nicole W Tsao; Marianna Leung
Journal:  Can J Kidney Health Dis       Date:  2014-12-19

9.  Randomised, Double-blind, Comparative Clinical Study of New Ranibizumab Biosimilar in Neovascular (Wet) Age-Related Macular Degeneration.

Authors:  Prasad Apsangikar; Pravin Ghadge; Manoj Naik; Santosh Nair; Ravikiran Payghan
Journal:  Clin Ophthalmol       Date:  2021-07-16

10.  Biosimilars: Current regulatory perspective and challenges.

Authors:  Diwakar Jha; Ram Kumar Mishra; Rishabh Pandey
Journal:  J Pharm Bioallied Sci       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.